Stocks Swing on Declaration: AT&T, Inc. (NYSE:T), Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), Biogen Inc. (NASDAQ:BIIB)

AT&T, Inc. (NYSE:T) [Trend Analysis] declared that wireline employees represented by the Communications Workers of America contain voted to approve a three-year agreement for the AT&T Midwest region. The tentative concord was reached May 13 and was unanimously authorized by the CWA bargaining committee that spent over nine weeks working by means of the firm’s bargaining team to reach a fair accord, according to the company. The company said the agreement covers about 12,000 employees in Illinois, Indiana, Michigan, Ohio and Wisconsin. It is retroactive to April 12, 2015. AT&T, Inc. (NYSE:T) stock price closed at $36.12 with the total traded volume of 29.89 Million shares. Its price to sales ratio ended at 1.42. Its market capitalization is 187.57 Billion. The stock owned by the Financial Institutions was 54.20% while by insiders was 0.05%.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) released that Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency (EMA) has adopted optimistic opinions recommending marketing approval of Strensiq and Kanuma. The offered indication for Strensiq is for long-term enzyme substitute therapy in patients with pediatric-onset hypophosphatasia (HPP) to treat the bone manifestations of the disease. The proposed indication for Kanuma is for long-term enzyme replacement therapy in patients of all ages with lysosomal acid lipase deficiency (LAL-d). Based on the CHMP’s positive recommendations, final decisions from the European Commission are expected in the third quarter of 2015, after which the Company will begin the country-by-country reimbursement processes. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) begun last trade with a price of $186.83 and throughout the trading session climbed at a high of $186.96. The day-trade ended with -0.78% to $184.45.

Global biotechnology firm, Biogen Inc. (NASDAQ:BIIB) and healthcare firm Swedish Orphan Biovitrum AB (SWTUY) reported that the European Medicines Agency (EMA) has believed the Marketing Authorization Application (MAA) of ALPROLIX (rFIXFc). This corroboration signifies the initiation of the EMA’s review process. The MAA includes results from two global, Phase 3 clinical trials examining the efficacy, safety and pharmacokinetics of ALPROLIX for hemophilia B. It also includes the pivotal B-LONG study for previously treated adults and adolescents, and Kids B-LONG study for previously treated children under age 12. ALPROLIX is a recombinant factor IX Fc fusion protein product candidate for the treatment of hemophilia B. Biogen Inc. (NASDAQ:BIIB) has the market capitalization of 96.15 Billion. Shares of firm plunged -0.62% to close at $408.73 with the total traded volume of 958061. The firm has current ratio of 2.70 for the most recent quarter.